Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ivan Melnikov und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Centre of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A 3-rd Cherepkovs…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
This review aimed to trace the inflammatory pathway from the NLRP3 inflammasome to monomeric C-reactive protein (mCRP) in atherosclerotic cardiovascular disease. CRP is the final product of the interleukin (IL)-1β/IL-6/CRP axis. Its monomeric form can be produced at sites of local inflammation through the dissociation of pentameric CRP and, to some extent, local synthesis. mCRP has a distinct proinflammatory profile. In vitro and animal-model studies have suggested a role for mCRP in: platelet activation, adhesion, and aggregation; endothelial activation; leukocyte recruitment and polarization; foam-cell formation; and neovascularization. mCRP has been shown to deposit in atherosclerotic plaques and damaged tissues. In recent years, the first published papers have reported the development and application of mCRP assays. Principally, these studies demonstrated the feasibility of measuring mCRP levels. With recent advances in detection techniques and the introduction of first assays, mCRP-level measurement should become more accessible and widely used. To date, anti-inflammatory therapy in atherosclerosis has targeted the NLRP3 inflammasome and upstream links of the IL-1β/IL-6/CRP axis. Large clinical trials have provided sufficient evidence to support this strategy. However, few compounds target CRP. Studies on these agents are limited to animal models or small clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Medical Research Centre of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A 3-rd Cherepkovskaya Street, 121552 Moscow, Russia.
- State Research Center of the Russian Federation, Institute of Biomedical Problems of Russian Academy of Sciences, 76A Khoroshevskoye Shosse, 123007 Moscow, Russia.
ORCID-Profile: Ivan Melnikov, Sergey Kozlov, Yuliya Avtaeva
Förderung
- Russian Science Foundation
Zitieren
APA
Melnikov, I., Kozlov, S., Saburova, O., Avtaeva, Y., Guria, K., & Gabbasov, Z. (2023). Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032079
Vancouver
Melnikov I, Kozlov S, Saburova O, Avtaeva Y, Guria K, Gabbasov Z. Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032079
BibTeX
@article{Melnikov2023,
author = {Melnikov, Ivan and Kozlov, Sergey and Saburova, Olga and Avtaeva, Yuliya and Guria, Konstantin and Gabbasov, Zufar},
title = {Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032079}
}
EUVIMED